Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 3, 2002, Pages 269-273

  Breathnach, O S ^a   Kasturi, V ^a   Kaye, F ^a   Herscher, L ^a   Georgiadis, M S ^a   Edison, M ^a   Schuler, B S ^a   Pizzella, P ^a   Steinberg, S M ^a   O'Neil, K ^a   Johnson, Bruce E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Carcinoma; Clinical trial; Lung neoplasm; Neoadjuvant; Non small cell lung cancer; Phase II

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; HISTAMINE H3 RECEPTOR ANTAGONIST; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREDICTION; SEPSIS; STROKE; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL ANALYSIS;

EID: 0036272381     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200206000-00013     Document Type: Article

References (26)

1. Long-term observations of the patterns of failure in patients with unresectable cell carcinoma of the lung treated with definitive radiotherapy: Report by the Radiation Therapy Oncology Group
2. A randomized phase I/II trial of hyperfractionated radiation therapy with total 60.0 Gy to 79.2 Gy: Possible survival benefit with > 69.6 Gy in favorable patient Radiation Therapy Oncology Group stage III non-small cell lung carcinoma: Report Radiation Therapy Oncology Group 83-11
3. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
4. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients
5. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
6. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves cytotoxicity
7. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial
8. Bronchioloalveolar carcinoma of the lung: Recurrences and survival in patients with stage I disease
9. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of a 96 hour infusion
10. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
11. A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer
12. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens
13. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
14. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule
15. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphoma
16. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer
17. Common toxicity criteria, version 2.0
18. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
19. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
20. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
21. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
22. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
23. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung
24. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Initial report of Radiation Therapy Oncology Group (RTOG) 9410
25. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer
26. Phase II evaluation of paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma (BAC)